Citations

Clear

2429 citation(s) found for "Shah, SS".

Treat-to-target of endoscopic remission in patients with inflammatory bowel disease in symptomatic remission on advanced therapies (QUOTIENT): rationale, design and protocol for an open-label, multicentre, pragmatic, randomised controlled trial
Singh, Siddharth , Nguyen, J. , Fudman, David , Gerich, Mark E. , Hudesman, David , McConnell, Ryan , Flynn, Ann D. , Hwang, Caroline, Sprung, Brandon, Gaidos, Jill , Mattar, Mark , Metwally, Mark, Ali, Tauseef , Narula, Neeraj, Rosenfeld, Greg , Cross, Raymond, Gaytán, Josep María, Gurrola, Emily-Sophinie, Patel, Sagar , Melmed, Gil , Weaver, Sarah , Power, Sydney, Jairath, Vipul , Hou, Jason K. , Jairath, Vipul , Jairath, Vipul , Fudman, David I , Hudesman, David , Flynn, Ann D , Sprung, Brandon , Gaidos, Jill K J , Ali, Tauseef , Hoentjen, Frank , Bessissow, Talat , Patel, Sagar , Siegel, Corey A , Zou, Guangyong , Jairath, Vipul , Jairath, V , Jairath, V , Melmed, Gil Y , Nguyen, Jasmine D, Shah, Shiraz Ali , Lukin, Dana J. , Rubin, David T. , Hashash, Jana G. , Ma, C , Narula, Neeraj , Bessissow, Talat , McCurdy, Jeffrey D , Ananthakrishnan, Ashwin N. , Gurrola, Emily-Sophinie, Power, Sydney , Zou, Guangyong

Mayo Clinic

BMJ Open Gastroenterology | April 1, 2025 | Volume: 12 | Issue: 1 | Pages: e001615

10.1136/bmjgast-2024-001615 | PMID 40164445 Get It

Introduction Targeted immunomodulators (eg, advanced therapies) effectively achieve symptomatic remission in patients with inflammatory bowel disease (IBD). However, ~25%–50% of patients with IBD achieving symptomatic remission with an advanced therapy may have continued endoscopically/radiologically active bowel inflammation, and it is uncertain whether changing alternative advanced therapies in asymptomatic patients with IBD will reduce bowel inflammation and achieve durable deep remission. Methods and analysis The QUality Outcomes Treating IBD to Target (QUOTIENT) study is an open-label, multicentre, pragmatic, randomised, controlled trial that aims to compare the efficacy and safety of switching to an alternative advanced therapy targeting endoscopic/radiological remission (treat-to-target) versus continuing the initial, or index, advanced therapy, in asymptomatic patients with IBD with moderate-to-severe endoscopic/radiological bowel inflammation. Enrolment is planned for ~250 participants in Canada/USA, randomised 1:1 to switching to alternative advanced therapy or continuing index advanced therapy, and then followed 104 weeks within routine clinical practice. Patient-reported outcomes measure efficacy and quality of life/treatment burden/safety. Primary endpoint is the time from randomisation to treatment failure. Ethics and dissemination The study is conducted in compliance with the protocol, ICH Good Clinical Practice, applicable regulatory requirements and appropriate review boards/independent ethics committees (approval numbers: Pro00077486; Pro00061437; STUDY00002062; 22-004171; i22-01269; IRB22-0890; IRB_00154397; 2000032384; SHIRB#2022.095-2; STUDY00007146; MMC#2024-18; REB#125290; 17784; Pro00142214; 20240660-01H), with documented written informed consent. Findings will be disseminated through peer-reviewed journals, scientific presentations, and publicly available Patient-Centered Outcomes Research Institute (PCORI) websites, including lay summaries. The Crohn’s & Colitis Foundation Education, Support, and Advocacy Department, and our patient advocacy stakeholder, will develop educational and marketing resources to communicate findings to a broad audience (>250 000 patients/caregivers/healthcare professionals). Trial registration number NCT05230173 .
Three-Dimensional Vector MR Elastography for Evaluating Tissue Mechanical Heterogeneity to Assess Liver Disease Progression
Wu, Hao , Zheng, Zhu, Li, Jiahui , Qiu, Caixin , Xu, Peng , Glaser, Kevin J. , Murphy, Matthew C. , Venkatesh, Sudhakar K. , Mounajjed, Taofic, Winkelmann, Christopher T. , Yashiro, Hiroaki , Manohar, Rohan, Shah, Vijay H. , Yin, Meng , Zhu, Zheng , Manduca, A , Winkelmann, Christopher T , Shah, Vijay H , Ehman, Richard , Yin, Meng , Venkatesh, Sudhakar K , Li, Jiahui , Wu, Hao , Yaqoob, Usman, Graham, Rondell P. , Manduca, Armando , Allen, Alina M. , Ehman, Richard L.

Mayo Clinic

Radiology | April 1, 2025 | Volume: 315 | Issue: 1 | Pages: No page available

10.1148/radiol.242349 | PMID 40167439 Get It

Spatial heterogeneity of liver viscoelasticity, measured at three-dimensional vector MR elastography, positively correlated with metabolic dysfunction–associated steatotic liver disease progression.
The diagnostic role of pharmacological provocation testing in cardiac electrophysiology: a clinical consensus statement of the European Heart Rhythm Association and the European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC, t
Behr, Elijah R. , Winkel, Bo Gregers , Ensam, Bode , Alfie, Alberto , Arbelo, Elena , Berry, Colin , Conte, Giulio , Crotti, Lia , Corcia, M. Cecilia Gonzalez , Kaski, Juan Carlos , Schulze‐Bahr, Eric , Wilde, Arthur A.M. , Tfelt‐Hansen, Jacob , Wolpert, Christian, Cuesta, Alejandro, Damman, Peter, Dobrev, Dobromir, Drago, Fabrizio, Haugaa, Kristina, Krahn, Andrew, Krause, Ulrich, Lambiase, Pier D, Napolitano, Carlo, Odening, Katja E, Shimizu, Wataru, Veltmann, Christian, Lambiase, Pier D. , Odening, Katja E. , Cerrone, Marina , Conte, Giulio , Crotti, Lia , Kaski, Juan Carlos , Nademanee, Koonlawee , Postema, Pieter G , Priori, Silvia , Probst, Vincent , Sarquella-Brugada, Georgia , Schulze-Bahr, Eric , Tadros, Rafik , Wilde, Arthur A M , Tfelt-Hansen, Jacob , Behr, Elijah Raphael , Lambiase, Pier D , Odening, Katja E , Arbelo, Elena , Berry, Colin , Cerrone, Marina , Nademanee, Koonlawee , Postema, Pieter G. , Priori, Silvia G. , Tadros, Rafik , Wolpert, Christian, Cuesta, Alejandro, Damman, Peter, Dobrev, Dobromir, Drago, Fabrizio, Haugaa, Kristina, Krahn, Andrew, Krause, Ulrich, Napolitano, Carlo, Shimizu, Wataru, Veltmann, Christian

Mayo Clinic

Europace | April 1, 2025 | Volume: 27 | Issue: 4 | Pages: No page available

10.1093/europace/euaf067 | PMID 40165484 Get It

Abstract The pharmacological provocation test is a pivotal tool in cardiac electrophysiology for the diagnosis of potential causes of sudden cardiac death, sudden cardiac arrest (SCA), arrhythmias, symptoms, or ECG abnormalities. The 2022 European Society of Cardiology Guidelines for the Treatment of Ventricular Arrhythmias and Prevention of Sudden Cardiac Death offered guidance on provocation testing but did not describe the indications and requirements in depth. This clinical consensus statement, led by the European Heart Rhythm Association and approved by major international stakeholders, aims to advise the general cardiologist and the arrhythmia expert who to test and when, where, and how to do it. The statement focuses on current practice for the diagnosis of subclinical arrhythmia syndromes and the causes of SCA, building upon the recommendations of the Guidelines. We address the sodium channel blocker provocation test for patients suspected of Brugada syndrome as well as the use of epinephrine, isoproterenol, adenosine, ergonovine, and acetylcholine.
Efficacy of Leadless Ultrasound-Based Left Ventricular Endocardial Pacing for Cardiac Resynchronization Therapy: A Meta-Analysis
Jain, Hritvik , Tariq, Muhammad Daoud , Jain, Jyoti , Singh, Jagjot, Shah, Siddharth , Patel, Nandan , Gardezi, Syed Khurram Mushtaq, Ahmed, Raheel, Gardezi, Syed K M , Khurram Mustaq Gardezi, Syed , Khan, Abdul Moiz , Zulfiqar, Eeshal , Ahmed, Mushood , Providência, Rui , Ahmed, Raheel , Chahal, C. Anwar A.

Mayo Clinic

Cardiology in Review | March 29, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/crd.0000000000000897 | PMID 40135909 Get It

Heart failure with reduced ejection fraction is a major cause of morbidity and mortality. Cardiac resynchronization therapy (CRT) improves outcomes but faces challenges such as unsuccessful lead placement and suboptimal responses. The Wireless Stimulation Endocardially for CRT (WiSE-CRT) system, a novel leadless left ventricular (LV) pacing technology, uses ultrasonic energy to deliver electrical stimulation directly to the LV endocardium, potentially improving the response rates. A comprehensive literature search was performed across multiple databases from inception until August 2024. The outcomes of interest included the New York Heart Association (NYHA) functional score, LV ejection fraction (LVEF), LV end-diastolic volume (LVEDV), LV end-systolic volume (LVESV), and QRS duration. Statistical analysis involved pooling the mean differences (MDs) and their corresponding 95% confidence intervals (CIs) from each study using the inverse-variance random-effects model in RevMan version 5.4.1 software. Seven studies, including 468 patients with heart failure treated with the WiSE-CRT system, were included. The pooled analysis showed significant improvements in NYHA functional score (MD: −0.44; 95% CI: −0.67 to −0.21; P = 0.0002; I 2 = 77%), LVEF (MD: 5.71; 95% CI: 4.54 to 6.87; P < 0.001), LVEDV (MD: −24.49; 95% CI: −33.24 to −15.73; P < 0.001), and LVESV (MD: −24.47; 95% CI: −32.80 to −16.14; P < 0.001). The QRS duration also decreased significantly (MD: −38.62; 95% CI: −46.76 to −30.49; P < 0.001; I 2 = 60%). The WiSE-CRT system significantly improved NYHA functional score, LVEF, QRS duration, LVEDV, and LVESV in patients with heart failure. This leadless pacing technology offers a promising alternative for ineligible candidates or for those who do not respond to conventional CRT.
Moderate alcohol-associated hepatitis: A real-world multicenter study
Idalsoaga, Francisco , Díaz, Luis Antonio , Dunn, Winston , Muñoz, Karen E., Caldentey, Vicente, Arnold, Jorge , Ayares, Gustavo , Mortuza, Rokhsana , Maiwall, Rakhi , Qian, Steve , Elfeki, Mohamed A. , Ramírez, Carolina , Malhi, Gurpreet, Ahmed, Adan, Homsi, Hoomam , Abid, Zinia, Echavarría, Victor, Poca, María , Cuyàs, Berta , Ventura‐Cots, Meritxell , Higuera‐de‐la‐Tijera, Fátima , Ayala-Valverde, María , Pérez, Diego , Gómez, Jaime , Abraldes, Juan, Al‐Karaghouli, Mustafa , Jalal, Prasun K. , Ibrahim, Mohamad Ali , García–Tsao, Guadalupe , Havaj, Daniel Ján , Sulejova, Karolina, Chacko, Kristina R. , Yaquich, Pamela, Toro, Luis, Shah, Vijay H. , Kamath, Patrick S. , Mehta, Heer , Arnold, Jorge , Ayares, Gustavo , Mortuza, Rokhsana , Sarin, Shiv Kumar , Maiwall, Rakhi , Qian, Steve , Simonetto, Douglas A , Singal, Ashwani K , Ramirez-Cadiz, Carolina , Poca, Maria , Soriano, German , Cuyas, Berta , Ventura Cots, Meritxell , Higuera-De La Tijera, Fatima , Ayala-Valverde, María , Jalal, Prasun K , Skladaný, Lubomir , Havaj, Daniel J , Chacko, Kristina R , Restrepo, Juan C , Shah, Vijay, Arrese, Marco , Kamath, Patrick S , Bataller, Ramon A , Díaz, Luis A , Elfeki, Mohamed A , Dunn, Winston , Echavaría, Victor , Muñoz, Karen, Zhang, Wei , Simonetto, Douglas A. , Singal, Ashwani K. , Ahmed, Adan, Abid, Zinia, Cabezas, Joaquín , Abraldeṣ, Juan G. , Goyes, Daniela , Selčanová, Světlana Adamcová , Rincón, Diego , Arrese, Marco , Arab, Juan Pablo

Mayo Clinic

Hepatology Communications | March 28, 2025 | Volume: 9 | Issue: 4 | Pages: No page available

10.1097/hc9.0000000000000673 | PMID 40131003 Get It

Background: Severe alcohol-associated hepatitis (sAH) is a well-characterized disease with high short-term mortality. However, there is limited research on those with a “less severe condition” (moderate AH). This study aims to characterize in-depth patients with moderate AH (mAH), including the performance of mortality scoring systems, key prognostic factors, and survival over time. Methods: A multicenter retrospective cohort study (2009–2019) included patients with mAH (MELD score ≤20 at admission). Cox regression and receiver operating characteristic curves with AUC were used for analysis. Results: We included 1845 patients with AH (20 centers, 8 countries) between 2009 and 2019. mAH was defined as a MELD score ≤20 at admission. Twenty-four percent met the criteria for an mAH episode. Patients with mAH tend to be older and have a higher proportion of females, with a median MELD of 17 (15–19), Maddrey discriminant function (mDF) of 33 (22–40), the trajectory of serum bilirubin of 0.83 (0.60–1.21), and neutrophil-to-lymphocyte ratio (NLR) of 5 (2.96–8.60). The primary causes of death in mAH included multiple organ failure (34.1%) and infections (16.6%). The cumulative survival rates at 30, 90, and 180 days were 94.3%, 90.4%, and 88.2%, respectively. In multivariable analysis, age was the only significant predictor of 30-day mortality (HR 1.49, 95% CI: 1.27–1.76, p <0.001). Mortality prediction models showed poor performance, with AUC for MELD (0.671), mDF (0.726), trajectory of serum bilirubin (0.733), and NLR (0.697). Conclusions: Patients with moderate AH exhibited a mortality of 11.8% at 6 months, primarily driven by multiple organ failure and infections. These patients also exhibit a different clinical profile compared to those with sAH. Tailored models and therapeutic strategies are needed to improve long-term outcomes in mAH.
Introducing STRAND: A Foundational Sequence Transformer for Range Adaptive Nucleotide Decoding
Ayanian, Shant , Korfiatis, Panos, Osborne, Collin , Molnar, Carl, Perez, Xoab, Xu, Clark , Das, Pravat, Callstrom, Matthew R. , Shah, Vijay H. , Ryu, Alexander J. , Venkatesh, Ganesh, Pondenkandath, Vinay, Vassilieva, Natalia , Kanakiya, Bhargav, Redlon, Matthew, Molnar, Carl , Blasi, Marc, Das, Pravat, Ryu, Alexander J. , Lazaridis, Konstantinos N. , Levin, May, Redlon, Matt , Myasoedova, Elena , Xu, Clark

Mayo Clinic

No container title available | March 28, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-6115078/v1 Get It

Abstract The advent of high-throughput sequencing has led to an exponential increase in genomic data, highlighting the need for efficient and accurate models to analyze and interpret this information. Here, we introduce a novel, exomic foundational model that leverages a combination of human reference genome and multispecies data to improve variant detection and interpretation. Our model utilizes a short- range transformer architecture and is trained on a large dataset of human exomic sequences derived from the Tapestry study. Through a series of ablation studies and scaling experiments, we demonstrate the effectiveness of our model in pre- dicting next token accuracy and identifying clinically pathogenic variants. We also show that our model outperforms existing models in a range of downstream tasks, including variant effect prediction and disease state identification. In fact, our largest STRAND variant (1B parameters) surpassed previous benchmarks, demonstrating a mean accuarcy of 0.880 (8.2% improvement over the original NT and 7% improvement over NT-v2). Furthermore, we construct a unique exomic ClinVar dataset to evaluate the model’s performance on pathogenicity and disease states. Our results highlight the potential of this model to improve our understanding of the human exome and its role in disease. The model and its applications have significant implications for genomic based diagnosis and personalized medicine including tailored therapeutic development.
Training and Performance of an Electrocardiogram-Enabled Machine Learning Model for Detection of Advanced Chronic Liver Disease
Rattan, Puru , Ahn, Joseph , Chara, Beatriz Sordi , Mullan, Aidan F. , Attia, Zachi I. , Friedman, Paul A. , Allen, Alina M. , Shah, Vijay H. , Kamath, Patrick S. , Ahn, Joseph C , Liu, Kan , Attia, Zachi I , Allen, Alina M , Kamath, Patrick S , Noseworthy, Peter A , Simonetto, Douglas A , Sordi Chara, Beatriz , Mullan, Aidan , Noseworthy, Peter A. , Simonetto, Douglas A.

Mayo Clinic

American Journal of Gastroenterology | March 28, 2025 | Volume: 120 | Issue: 10 | Pages: 2452-2456

10.14309/ajg.0000000000003433 | PMID 40146029 Get It

INTRODUCTION: Building on prior results, we hypothesized that an electrocardiogram (ECG)-enabled machine learning (ML) model could be used to detect advanced chronic liver disease (CLD). METHODS: A cohort with CLD and 12-lead ECGs was matched with controls from electronic health records. A ML model was trained as a binary classifier. RESULTS: There are 12,930 patients with CLD and 64,577 controls in the cohort. The model's discriminative ability to classify CLD showed an area under the receiver-operating characteristic curve 0.858 (95% confidence interval: 0.850–0.866), and at the chosen threshold, CLD ECGs had 12 times higher odds of being classified as CLD (diagnostic odds ratio 12.33, 95% confidence interval: 11.16–13.63). DISCUSSION: An ECG-enabled ML model affords great promise in identifying advanced CLD in low resource areas.
Late-Onset Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy
Durbin, Sienna , Zubiri, Leyre , Perlman, Katherine, Wu, Chia‐Yun, Lim, Tristan , Grealish, Kelley, Hathaway, Nora , Jacoby, Ted V. , Shah, Nishi , Mooradian, Meghan J. , Reynolds, Kerry L. , Zubiri, Leyre , LoPiccolo, Jaclyn , Wang, Mike , Falade, Ayo , Molina, Gabriel E.

Mayo Clinic

JAMA Network Open | March 27, 2025 | Volume: 8 | Issue: 3 | Pages: e252668

10.1001/jamanetworkopen.2025.2668 | PMID 40146104 Get It

Importance The use of immune checkpoint inhibitors (ICIs) is increasing. Little is known about the frequency of late-onset immune-related adverse events (irAEs) and the patient-specific risk factors associated with their development. Objectives To assess the incidence of persistent or de novo late-onset irAEs requiring hospitalization and identify patient factors associated with risk of late-onset irAEs. Design, Setting, and Participants This retrospective observational cohort study conducted from January 2011 to October 2022 included patients who received ICIs and were hospitalized with irAEs at an academic medical center. Exclusion criteria included ICI therapy outside of the hospital system and no irAE diagnosis during admission. Data were analyzed from November 15, 2022, to January 8, 2025. Exposure Late-onset irAEs. Main Outcomes and Measures The main study outcomes were (1) incidence of irAE hospitalization at 0 to 6 months (early), more than 6 to 12 months (intermediate), and more than 12 months (late) after ICI initiation and (2) patient factors associated with risk of late-onset irAEs. Results Among the 795 patients hospitalized with irAEs, the median age was 67.3 years (IQR, 58.3-74.8 years); 476 (59.9%) were male. Most patients (n = 517 [65.0%]) received anti–programmed death ligand 1 (PD-L1) and anti–programmed cell death 1 monotherapy, with the most common indications being melanoma (n = 335 [42.1%]) and lung cancer (n = 167 [21.0%]). The median time from start of ICI therapy to hospital admission was 2.7 months (IQR, 1.2-6.1 months), with 14.7% of patients (n = 117 of 795) presenting 6 to 12 months after initial ICI exposure and 10.8% of patients (86 of 795) presenting more than 12 months after initial exposure. The irAEs most likely to present late included those involving the kidney (10 of 32 [31.3%]) and hematologic (5 of 23 [21.7%]) organ systems. In univariate analysis, ICI type was significantly associated with the timing of hospital admission for irAEs; of the 517 patients receiving anti–PD-L1–based therapy, 13.5% (n = 70) presented late compared with 5.4% (9 of 167) receiving dual therapy with anti–cytotoxic T-lymphocyte–associated protein 4 ( P &amp;lt; .001). Patients receiving perioperative ICI therapy were significantly more likely to be admitted at the intermediate interval (16 of 68 [23.5%]) compared with those with metastatic disease (87 of 678 [12.8%]) ( P = .03). Timing of irAE was also significantly associated with active ICI exposure; among the patients presenting late, 7.4% (48 of 651) had received ICI therapy within the last 60 days compared with 26.4% (38 of 144) who had not had recent ICI exposure ( P &amp;lt; .001). Conclusions and Relevance The findings of this retrospective observational cohort study suggest that late irAEs are possible, with a subset of patients presenting years after the start of ICI therapy. Clinicians must remain vigilant for irAEs regardless of elapsed time from ICI therapy, especially as patients live longer and ICIs become more widely used. Future investigations are needed to better understand the risk factors for late-onset irAEs and the distinct immunologic pathways that underlie such events.
Assessing hepatic arterial injuries in the setting of normothermic machine perfusion in liver transplantation: A noninvasive approach
Bodzin, Adam S. , MacConmara, Malcolm , Attia, Magdy , Perry, Dana K. , Shah, Ashesh P. , MacConmara, Malcolm P

Mayo Clinic

Liver Transplantation | March 26, 2025 | Volume: 31 | Issue: 11 | Pages: 1436-1439

10.1097/lvt.0000000000000610 | PMID 40130999 Get It

Sociodemographic Characteristics of Patients Seen at Vascular Anomaly Centers in the United States
Sisk, Bryan A. , Eng, Whitney , Mack, Joana M. , Tran, Andrew , Ogino, Jayme , Pearson, Erika , Bies, Joshua J., Smink, Gayle , Shah, Sonal D. , Mohney, Lindsey , Fassel, Hannah, Schulte, Rachael , Tessem, Renae A., Swaminathan, Neeraja , McLean, Thomas W. , Alturky, Sara , Wu, Melinda , Atkinson, Autumn, Al‐Huniti, Ahmad , Massey, Gita , Engel, Elissa , Echols, Tyson C. , Kumar, Sumukh Arun , Fox, Michael D. , King, Katherine A., Mack, Joana , Pearson, Erika , Shah, Sonal D , Swaminathan, Neeraja , McLean, Thomas W , Blatt, Julie , Massey, Gita , Ricci, Kiersten , Echols, Tyson , Fox, Michael , Sisk, Bryan A , Aye, Jamie M. , Chang, Vivian Y. , Hogeling, Marcia , Atkinson, Autumn

Mayo Clinic

Pediatric Blood & Cancer | March 17, 2025 | Volume: 72 | Issue: 6 | Pages: No page available

10.1002/pbc.31661 | PMID 40091541 Get It

ABSTRACTPatients with vascular anomalies (VAs) require expert multidisciplinary care. No prior studies have characterized the sociodemographic characteristics across multiple VA centers. We collected data on 5783 patients receiving care at 20 VA centers between July 1, 2020 through December 31, 2022. Male patients were underrepresented compared to the state‐level census data at 17/20 centers. Black and Asian patients were underrepresented at 14/20 and 12/20 centers, respectively. The median distance to the hospital was 48 miles, and median age was 12.0 years. These data suggest that race, sex, age, and distance from the hospital could impede the ability to access expert VA care.